WO2004014361A1 - Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity - Google Patents
Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity Download PDFInfo
- Publication number
- WO2004014361A1 WO2004014361A1 PCT/EP2003/008153 EP0308153W WO2004014361A1 WO 2004014361 A1 WO2004014361 A1 WO 2004014361A1 EP 0308153 W EP0308153 W EP 0308153W WO 2004014361 A1 WO2004014361 A1 WO 2004014361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carob
- content
- process according
- denatured
- carob flour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C[C@]1(*)C=C=C(*)CC1 Chemical compound C[C@]1(*)C=C=C(*)CC1 0.000 description 5
- GZGNCMFQMAVHSL-UHFFFAOYSA-N O=Cc(nc1)nc2c1OCCO2 Chemical compound O=Cc(nc1)nc2c1OCCO2 GZGNCMFQMAVHSL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- Denatured carob flour and the process to obtain it described in this specification will be applied in industry to develop dietary fiber products rich in condensed tannins for human consumption.
- Carob pulp is also rich in cyclitol and pinitol, a product that is transformed into inositol in the organism, a molecule of great interest for cell metabolism control (Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharacol (2000) 130 (8): 1944-48).
- the object of the present invention is, therefore, to eliminate from the carob pulp a large proportion of its sugars and soluble tannins, but maintaining a significant pinitol contents and to modify its condensed tannins to maintain its beneficial effects (hypolipaemic activity), regulators of intestinal function, antioxidants etc), eliminate its astringent and antinutritional effects and to be able to use in this way the product as a dietary product for human or animal use, as well as a component in pharmaceuticals.
- the denatured carob flour with low soluble tannin and sugar contents has the following composition, depending on the variety of fruit used:
- Cyclitols usually 0.2-1.5%; typically 0.3-1%
- Lignins usually 2-10% ; typically 2-7%
- Celluloses usually 10-30% ; typically 15-28%
- Hemicelluloses usually 3-20% ; typically 3-9% Pectins usually 1-6%; typically 2-5%
- Condensed tannins usually 25-55%; typically 30-48%
- Protein usually 3-9%; typically 4-8% Water contents less than usually below 8%; typically below
- This carob flour is characterized by having an active ingredient with at least 25%, usually 30%, typically 40% of condensed carob tannins denatured thermally with a weight ratio of soluble to insoluble polyphenols less than 0.05 (solubility determined with water at 37°C). Evaluation of the polyphenol contents has been carried out by first determining the soluble tannin contents in water at 37°C stirring for 15 minutes; these are determined spec trophotrometric ally in this water with the Folin-Ciocalteau reagent (Singleton N.L. Rossi J.A. Colorimetry of total phenolics with phosphomolybdicphosphotungstic acid reagents. Am. J. Enol. Nitic (1965). 16:144- 158).
- the insoluble polyphenols of the residue are determined by treatment with HC1- butanol according to the method of Hagerman and coworkers (Hagerman A.E. Zhao Y. Jonson S. Methods for determination of condensed and hydrolyzable tannins. In F. Shahidi (Ed), Antinutrients and phytochemicals in foods (p. 209-222). ACS symposium Series 662. Washington, DC. American Chemical Society).
- carob pulp rich in condensed tannins, formed by polymerization of flavan-3-ol and its gallic esters with a strong astringent effect, are treated with heat (between usually 130 and 200°C, typically 140 and 150°C) to result in a change of structure of the polyphenols with partial degradation and polymerization and to eliminate astringency and interference with absorption of nutrients in the diet but maintaining most of its positive effects.
- the process to obtain the previously described carob flour consists in a series of steps, as follows: a. Cleaning the whole fruit: Cleaning includes e.g dry (e.g. mechanical separation of contaminants) or wet (e.g. wash out with water) cleaning steps. Dependent on the cleaning procedure this step may additionally include a drying step. This could be done e.g. in an air flow, b. Crushing the carob fruits: this could be done, e.g. by passing the carob fruit through a mill, typically a hammer mill, to shred the pods to pieces smaller than 3 cm. c.
- a. Cleaning the whole fruit Cleaning includes e.g dry (e.g. mechanical separation of contaminants) or wet (e.g. wash out with water) cleaning steps. Dependent on the cleaning procedure this step may additionally include a drying step. This could be done e.g. in an air flow, b. Crushing the carob fruits: this could be done, e.g. by passing the carob fruit through a mill, typically a
- the seed can be separated using a sieve with a suitably sized mesh, depending on the conditions of the process, the agronomical variety and the water contents of the fruit.
- air classification or other mechanical or physical technologies can be used.
- Toasting modification of the structure of condensed tannins: this process is important to change the nutritional properties of the condensed tannins. This can be reached by toasting of the carob kibbles at temperatures usually between 130-200°C, typically between 140-150°C for a certain time period depending on the water content of the pulp and the particle size. Usual time periods for this toasting process are 5-60 minutes, typically 10-20 minutes.
- Extraction process the toasted carob pulp is extracted with water or any other suitable solvent to remove the sugars and water-soluble tannins.
- the ratio of extraction material to solvent is usually higher than 1:20 (by weight), typically 1:4 (by weight).
- the extraction can be made at different temperatures usually in the range of 5-80°C, typically between 20-55°C.
- Extraction can be done e.g. in an simple extraction tank (with or without stirrer) or in a continuously operating extractor (counter current flow extraction). Dependent on the other extraction parameters extraction time usually lies between 5 minutes to 24 hours, typically between 15 minutes and 2 hours.
- Separation Separation of the water soluble components from the water insoluble parts can be done by several techniques including decantation, filtration, or centrifugation.
- Milling the water-insoluble residue is ground to a fine powder by milling techniques. Preferred equipment is a colloidal mill, but also other milling techniques can be considered (e.g. ball mills). Reached particle sizes are below
- 250 ⁇ m (90% of particles below 250 ⁇ m), usually below 150 ⁇ m (90% of particles below 150 ⁇ m) and typically below 100 ⁇ m (90% of particles below
- steps e. (extraction) and f. (separation) are sufficient to reach sugar contents usually below 15 % and typically below 10% in the insoluble residue.
- steps e. (extraction) and f. (separation) are sufficient to reach sugar contents usually below 15 % and typically below 10% in the insoluble residue.
- i. Separation After the last extraction step the obtained residue is pressed, filtered, decanted, or centrifuged to eliminate as much as possible of the water, j. Drying: To reduce the water content usually below 8%, typically below 6%.
- the whole production process, as described above in the steps a-k, or parts of it, can also be done in a continuous way.
- DCF Dynamic Carob Fibre
- the DCF increases fecal volume and weight compared to cellulose and results in a similar fecal volume and weight, at the same doses, as NCF, but with fecal butyrate and polyphenol concentrations 30% and 10% higher, respectively, in rats fed with our invention than in those fed with diets containing carob fiber (NCF), hence, as repeatedly described by several authors, protection against the formation of mutagenic or carcinogenic compounds (electrophylic molecules) in animals that consume DCF is higher than that achieved with carob fibers (NCF).
- NCF carob fiber
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004526773A JP4515260B2 (ja) | 2002-07-25 | 2003-07-23 | アミノシクロヘキセンキノリンおよび抗菌活性を有するそのアザアイソステリック類似体 |
| EP03784064A EP1539133B1 (en) | 2002-07-25 | 2003-07-23 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity |
| DE60307860T DE60307860T2 (de) | 2002-07-25 | 2003-07-23 | Aminocyclohexenchinoline und ihre azaisosterischen Analoga mit antibakterieller Wirkung |
| US10/522,058 US20060040925A1 (en) | 2002-07-25 | 2003-07-23 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity |
| AU2003251474A AU2003251474A1 (en) | 2002-07-25 | 2003-07-23 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0217294.8 | 2002-07-25 | ||
| GBGB0217294.8A GB0217294D0 (en) | 2002-07-25 | 2002-07-25 | Medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004014361A1 true WO2004014361A1 (en) | 2004-02-19 |
| WO2004014361A9 WO2004014361A9 (en) | 2004-04-08 |
Family
ID=9941121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2003/008153 Ceased WO2004014361A1 (en) | 2002-07-25 | 2003-07-23 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060040925A1 (enExample) |
| EP (1) | EP1539133B1 (enExample) |
| JP (1) | JP4515260B2 (enExample) |
| AT (1) | ATE336995T1 (enExample) |
| AU (1) | AU2003251474A1 (enExample) |
| DE (1) | DE60307860T2 (enExample) |
| ES (1) | ES2270142T3 (enExample) |
| GB (1) | GB0217294D0 (enExample) |
| WO (1) | WO2004014361A1 (enExample) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006010040A3 (en) * | 2004-07-09 | 2006-05-04 | Glaxo Group Ltd | Antibacterial agents |
| US7109213B2 (en) | 2002-01-29 | 2006-09-19 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| US7232832B2 (en) | 2002-11-05 | 2007-06-19 | Smithkline Beecham Corporation | Antibacterial agents |
| WO2007086016A1 (en) | 2006-01-26 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Tetrahydropyrane antibiotics |
| WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
| US7312212B2 (en) | 2002-01-29 | 2007-12-25 | Glaxo Group Limited | Aminopiperidine derivatives |
| WO2008003690A1 (en) | 2006-07-03 | 2008-01-10 | Glaxo Group Limited | Azatricyclic compounds and their use |
| WO2008009700A1 (en) | 2006-07-20 | 2008-01-24 | Glaxo Group Limited | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
| US7491714B2 (en) | 2002-12-04 | 2009-02-17 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
| US7498326B2 (en) | 2002-06-26 | 2009-03-03 | Glaxo Group Limited | Compounds |
| EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
| US7618959B2 (en) | 2002-11-05 | 2009-11-17 | Smithklinebeecham Corp | Antibacterial agents |
| US7622481B2 (en) | 2002-06-26 | 2009-11-24 | Glaxo Group Limited | Antibacterial compounds |
| US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
| WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
| US7709496B2 (en) | 2006-04-06 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
| WO2010081874A1 (en) | 2009-01-15 | 2010-07-22 | Glaxo Group Limited | Naphthyridin-2 (1 h)-one compounds useful as antibacterials |
| US7875715B2 (en) | 2005-06-16 | 2011-01-25 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| US7999115B2 (en) | 2006-08-30 | 2011-08-16 | Actelion Pharmaceutical Ltd. | Spiro antibiotic derivatives |
| US9127002B2 (en) | 2012-02-10 | 2015-09-08 | Actelion Pharmaceuticals Ltd | Process for manufacturing a naphthyridine derivative |
| WO2016027249A1 (en) | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
| WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
| EP3896066A2 (de) | 2015-08-07 | 2021-10-20 | Bayer CropScience Aktiengesellschaft | 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0118238D0 (en) * | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
| AR042486A1 (es) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
| EP1991540A1 (en) * | 2006-02-21 | 2008-11-19 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009528365A (ja) * | 2006-02-28 | 2009-08-06 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのシンノリン及びキナゾリン誘導体 |
| MX2008011257A (es) * | 2006-03-08 | 2008-09-25 | Amgen Inc | Derivados de quinolina e isoquinolina como inhibidores de fosfodiesterasa 10. |
| PL2137196T3 (pl) * | 2007-04-20 | 2011-03-31 | Glaxo Group Ltd | Tricykliczne związki zawierające azot jako środki przeciwbakteryjne |
| JP6022691B2 (ja) * | 2012-08-30 | 2016-11-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ジオキシノ−及びオキサジン−[2,3−d]ピリミジンpi3k阻害剤化合物及び使用方法 |
| WO2021076886A1 (en) | 2019-10-18 | 2021-04-22 | The Regents Of The University Of California | 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders |
| CN119161260A (zh) * | 2024-06-26 | 2024-12-20 | 安徽大学 | 一种1-(2-氨基-4-氟-5-甲氧基苯基)-1-丙酮的合成方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078748A1 (en) * | 1999-06-21 | 2000-12-28 | Smithkline Beecham P.L.C. | Quinoline derivatives as antibacterials |
| WO2001007432A2 (en) * | 1999-07-23 | 2001-02-01 | Smithkline Beecham P.L.C. | Aminopiperidine derivatives as antibacterials |
| WO2001007433A2 (en) * | 1999-07-23 | 2001-02-01 | Smithkline Beecham P.L.C. | Quinoline derivatives and their use as antibacterial agents |
| WO2002008224A1 (en) * | 2000-07-26 | 2002-01-31 | Smithkline Beecham P.L.C. | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| WO2002056882A1 (en) * | 2001-01-22 | 2002-07-25 | Smithkline Beecham P.L.C. | Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0790981B1 (en) * | 1994-11-10 | 1999-09-08 | Pfizer Inc. | Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas as 5-lipoxygenase inhibitors |
| WO1999037635A1 (en) * | 1998-01-26 | 1999-07-29 | Smithkline Beecham Plc | Quinoline derivatives as antibacterials |
| GB9822450D0 (en) * | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
| AU2437900A (en) * | 1999-01-20 | 2000-08-07 | Smithkline Beecham Plc | Piperidinylquinolines as protein tyrosine kinase inhibitors |
| FR2816618B1 (fr) * | 2000-11-15 | 2002-12-27 | Aventis Pharma Sa | Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent |
| GB0031088D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
-
2002
- 2002-07-25 GB GBGB0217294.8A patent/GB0217294D0/en not_active Ceased
-
2003
- 2003-07-23 DE DE60307860T patent/DE60307860T2/de not_active Expired - Lifetime
- 2003-07-23 AU AU2003251474A patent/AU2003251474A1/en not_active Abandoned
- 2003-07-23 US US10/522,058 patent/US20060040925A1/en not_active Abandoned
- 2003-07-23 JP JP2004526773A patent/JP4515260B2/ja not_active Expired - Fee Related
- 2003-07-23 ES ES03784064T patent/ES2270142T3/es not_active Expired - Lifetime
- 2003-07-23 AT AT03784064T patent/ATE336995T1/de not_active IP Right Cessation
- 2003-07-23 EP EP03784064A patent/EP1539133B1/en not_active Expired - Lifetime
- 2003-07-23 WO PCT/EP2003/008153 patent/WO2004014361A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078748A1 (en) * | 1999-06-21 | 2000-12-28 | Smithkline Beecham P.L.C. | Quinoline derivatives as antibacterials |
| WO2001007432A2 (en) * | 1999-07-23 | 2001-02-01 | Smithkline Beecham P.L.C. | Aminopiperidine derivatives as antibacterials |
| WO2001007433A2 (en) * | 1999-07-23 | 2001-02-01 | Smithkline Beecham P.L.C. | Quinoline derivatives and their use as antibacterial agents |
| WO2002008224A1 (en) * | 2000-07-26 | 2002-01-31 | Smithkline Beecham P.L.C. | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| WO2002056882A1 (en) * | 2001-01-22 | 2002-07-25 | Smithkline Beecham P.L.C. | Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109213B2 (en) | 2002-01-29 | 2006-09-19 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| US7312212B2 (en) | 2002-01-29 | 2007-12-25 | Glaxo Group Limited | Aminopiperidine derivatives |
| US7622481B2 (en) | 2002-06-26 | 2009-11-24 | Glaxo Group Limited | Antibacterial compounds |
| US7498326B2 (en) | 2002-06-26 | 2009-03-03 | Glaxo Group Limited | Compounds |
| US7232832B2 (en) | 2002-11-05 | 2007-06-19 | Smithkline Beecham Corporation | Antibacterial agents |
| US7618959B2 (en) | 2002-11-05 | 2009-11-17 | Smithklinebeecham Corp | Antibacterial agents |
| US7491714B2 (en) | 2002-12-04 | 2009-02-17 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
| US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
| WO2006010040A3 (en) * | 2004-07-09 | 2006-05-04 | Glaxo Group Ltd | Antibacterial agents |
| US8124602B2 (en) | 2005-06-16 | 2012-02-28 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| US7875715B2 (en) | 2005-06-16 | 2011-01-25 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| WO2007086016A1 (en) | 2006-01-26 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Tetrahydropyrane antibiotics |
| US7709496B2 (en) | 2006-04-06 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
| WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
| WO2008003690A1 (en) | 2006-07-03 | 2008-01-10 | Glaxo Group Limited | Azatricyclic compounds and their use |
| WO2008009700A1 (en) | 2006-07-20 | 2008-01-24 | Glaxo Group Limited | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
| US7999115B2 (en) | 2006-08-30 | 2011-08-16 | Actelion Pharmaceutical Ltd. | Spiro antibiotic derivatives |
| EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
| WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
| WO2010081874A1 (en) | 2009-01-15 | 2010-07-22 | Glaxo Group Limited | Naphthyridin-2 (1 h)-one compounds useful as antibacterials |
| US9127002B2 (en) | 2012-02-10 | 2015-09-08 | Actelion Pharmaceuticals Ltd | Process for manufacturing a naphthyridine derivative |
| WO2016027249A1 (en) | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
| EP3639824A1 (en) | 2014-08-22 | 2020-04-22 | GlaxoSmithKline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
| EP3896066A2 (de) | 2015-08-07 | 2021-10-20 | Bayer CropScience Aktiengesellschaft | 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel |
| EP3896065A1 (de) | 2015-08-07 | 2021-10-20 | Bayer CropScience Aktiengesellschaft | 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel |
| WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1539133B1 (en) | 2006-08-23 |
| DE60307860T2 (de) | 2007-10-11 |
| AU2003251474A1 (en) | 2004-02-25 |
| WO2004014361A9 (en) | 2004-04-08 |
| GB0217294D0 (en) | 2002-09-04 |
| ES2270142T3 (es) | 2007-04-01 |
| AU2003251474A8 (en) | 2004-02-25 |
| JP2005538125A (ja) | 2005-12-15 |
| US20060040925A1 (en) | 2006-02-23 |
| EP1539133A1 (en) | 2005-06-15 |
| JP4515260B2 (ja) | 2010-07-28 |
| ATE336995T1 (de) | 2006-09-15 |
| DE60307860D1 (de) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004014361A1 (en) | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | |
| US6855359B2 (en) | Soluble isoflavone compositions | |
| PB Gollucke et al. | Use of grape polyphenols for promoting human health: a review of patents | |
| EP1549156B1 (en) | Denatured carob flour (dcf) with a low content of soluble tannins and sugars, meant for human consumption and process to obtain it | |
| KR20190054542A (ko) | 녹차 추출물 제조방법 및 이로부터 제조된 녹차 추출물 | |
| JP3359298B2 (ja) | かんきつ果汁由来のカロチノイド高含有粉末の製造方法 | |
| JP2003146898A (ja) | 高脂血症改善剤 | |
| JPH09262066A (ja) | 高脂血症を抑制するための食品および医薬組成物 | |
| US9132159B2 (en) | Composition for prevention and/or treatment of tumors containing acacia derivative | |
| JP2003325136A (ja) | 関節炎改善用食品 | |
| JPH0840923A (ja) | 栄養補助剤 | |
| JP2003095965A (ja) | 高血圧症の予防・治療剤 | |
| KR20180130957A (ko) | 기능성분이 증대된 새싹보리 추출물 제조방법 및 이를 함유한 기능성 식품 | |
| US20060251744A1 (en) | Method for preparing ginkgo extracts having a reduced content of polycyclic aromatic hydrocarbons | |
| JP2009107952A (ja) | 抗骨粗鬆症剤 | |
| ES2602877B1 (es) | Procedimiento de obtención de un concentrado de proantocianidinas poliméricas con un contenido superior al 90% mediante tratamientos enzimáticos y sin utilización de disolventes orgánicos | |
| JP2016108265A (ja) | 持続性抗酸化剤 | |
| US8178135B2 (en) | Aqueous solution of conophylline and/or conophyllidine | |
| JP2008503542A (ja) | プロアントシアニジンを含有する植物由来の製品及びその製法 | |
| KR20250133531A (ko) | 인디루빈(Indirubin), 데커시놀(Decursinol), 죽력을 이용한 탈모방지 효능을 가지는 조성물 | |
| CN117442701A (zh) | 一种提高抵抗力的茶叶和中药组合物及其制备方法 | |
| KR20240035028A (ko) | 수용화 커큐민과 밀겨 추출물을 이용한 인지 능력 개선용 조성물 | |
| JP4847712B2 (ja) | アカシア属樹皮由来物を含有する抗酸化組成物 | |
| CN117794393A (zh) | 口服组合物 | |
| TW202010506A (zh) | 菱角殼萃取物及其抑制乙醯膽鹼酯酶及治療或預防退化性疾病之應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| COP | Corrected version of pamphlet |
Free format text: DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION, REPLACE ALL PAGES BY CORRECT PAGES (59 PAGES) |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003784064 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004526773 Country of ref document: JP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003784064 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2006040925 Country of ref document: US Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10522058 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 10522058 Country of ref document: US |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2003784064 Country of ref document: EP |